Drugs / Olimel N12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04094038 | Sep 2019 → Apr 2024 overdue | end stage renal failure, muscular atrophy, protein-energy malnutrition | Erasmus Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Olimel N12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04094038 ↗ |